Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Zhang, Li Song ^a   Wang, Shu Qing ^a   Xu, Wei Ren ^b   Wang, Run Ling ^a   Wang, Jing Fang ^c,d  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c Chinese National Human Genome Center at Shanghai   (China)

^d SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LY 465608; LY 465908; MOLECULAR SCAFFOLD; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CONFORMATION; CONTROLLED STUDY; CORE HOPPING ALGORITHM; DRUG ABSORPTION; DRUG ACTIVATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE;

CATALYTIC DOMAIN; HUMANS; HYDROGEN BONDING; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PPAR ALPHA; PPAR GAMMA; PPAR-BETA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84868329975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048453     Document Type: Article

References (40)

1. Wild S, Roglic G, Green A, Sicree R, King H, (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
2. Zimmet P, Shaw J, Alberti KG, (2003) Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 20: 693-702.
3. Berger J, Moller DE, (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
4. Berger JP, Akiyama TE, Meinke PT, (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26: 244-251.
5. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, et al. (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142: 4195-4202.
6. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403.
7. Tenenbaum A, Motro M, Fisman EZ, (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4: 14.
8. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA, (2006) Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26: 28-40.
9. Cabrero A, Llaverias G, Roglans N, Alegret M, Sanchez R, et al. (1999) Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. Biochem Biophys Res Commun 260: 547-556.
10. Kasuga J, Oyama T, Hirakawa Y, Makishima M, Morikawa K, et al. (2008) Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part. Bioorg Med Chem Lett 18: 4525-4528.
11. Luquet S, Gaudel C, Holst D, Lopez-Soriano J, Jehl-Pietri C, et al. (2005) Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta 1740: 313-317.
12. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, et al. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 100: 15924-15929.
13. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, et al. (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 103: 3444-3449.
14. Willson TM, Brown PJ, Sternbach DD, Henke BR, (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550.
15. Calkin AC, Thomas MC, Cooper ME, (2003) MK-767. Kyorin/Banyu/Merck. Curr Opin Investig Drugs 4: 444-448.
16. Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, et al. (2005) Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 27: 1181-1195.
17. Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, et al. (2005) Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48: 1716-1725.
18. Pickavance LC, Brand CL, Wassermann K, Wilding JP, (2005) The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 144: 308-316.
19. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, et al. (2001) Structure of the PPARalpha and-gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9: 699-706.
20. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, et al. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 98: 13919-13924.
21. Banks JL, Beard HS, Cao Y, Cho AE, Damm W, et al. (2005) Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem 26: 1752-1780.
22. Wang JF, Chou KC, (2012) Insights into the mutation-induced HHH syndrome from modeling human mitochondrial ornithine transporter-1. PLoS One 7: e31048.
23. Wang JF, Chou KC, (2011) Insights from modeling the 3D structure of New Delhi metallo-beta-lactamse and its binding interactions with antibiotic drugs. PLoS One 6: e18414.
24. Wang JF, Wei DQ, Li L, Zheng SY, Li YX, et al. (2007) 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun 355: 513-519. Erratum in: Biochem Biophys Res Commun 2007, 357: 330; Biochem Biophys Res Commun 2009 384: 399.
25. Wang JF, Wei DQ, Chen C, Li Y, Chou KC, (2008) Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept Lett 15: 27-32.
26. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005) GROMACS: fast, flexible, and free. J Comput Chem 26: 1701-1718.
27. Oostenbrink C, Soares TA, van der Vegt NF, van Gunsteren WF, (2005) Validation of the 53A6 GROMOS force field. Eur Biophys J 34: 273-284.
28. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363.
29. Lian P, Wei DQ, Wang JF, Chou KC, (2011) An allosteric mechanism inferred from molecular dynamics simulations on phospholamban pentamer in lipid membranes. PLoS One 6: e18587.
30. Wang YJ, Wang JF, Ping J, Yu Y, Wang Y, et al. (2012) Computational studies on the substrate interactions of influenza A vuris PB2 subunit. PLoS One 7: e44079.
31. Wang Y, Wei DQ, Wang JF, (2010) Molecular dynamics studies on T1 lipase: insight into a double-flap mechanism. J Chem Inf Model 50: 875-878.
32. Ping J, Wang YJ, Wang JF, Li X, Shao ZF, et al. (2012) Negative cooperativity binding properties of human cytochrome P450 2E1 with monocyclic substrates. Curr Drug Metab 13: 1024-1031.
33. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690.
34. Li J, Wei DQ, Wang JF, Li YX, (2011) A negative cooperativity mechanism of human CYP2E1 inferred from molecular dynamics simulations and free energy calculations. J Chem Inf Model 51: 3217-3225.
35. Wang JF, Hao P, Li YX, Dai JL, Li X, (2012) Exploratioin of conformational transition in the aryl-binding site of human FXa using molecular dynamics simulations. J Mol Model 18: 2717-2725.
36. Gu H, Chen HF, Wei DQ, Wang JF, (2010) Molecular dynamics simulations exploring drug resistance in HIV-1 protease. Chinese Sci Bull 55: 2677-2683.
37. Wang JF, Zhang CC, Wei DQ, Li YX, (2010) Docking and molecular dynamics studies on CYP2D6. Chinese Sci Bull 55: 1877-1880.
38. Zeng QK, Du HL, Wang JF, Wei DQ, Wang XN, et al. (2009) Reversal of coenzyme specificity and improvement of catalytic efficiency of Pichia stipitis xylose reductase by rational site-directed mutagenesis. Biotechnol Lett 31: 1025-1029.
39. Chen Q, Zhang T, Wang JF, Wei DQ, (2011) Advances in human cytochrome P450 and personalizd medicine. Curr Drug Metab 12: 436-444.
40. Wang Y, Wu XL, Wei DQ, Li YX, Wang JF, (2012) Autoinhibitory mechanism for the mutation-induced impaired FGF9 signaling. J Chem Inf Model 52: 2422-2429.